Aprotinin counteracts heparin-induced inhibition of platelet contractile force (Q44318746)

1 December 2017

Aprotinin counteracts heparin-induced inhibition of platelet contractile force (English)

1 reference

1 December 2017

Marcus E Carr

1

1 reference

1 December 2017

Sheryl L Carr

2

1 reference

1 December 2017

Veronica Roa

3

1 reference

1 December 2017

Kathleen A McCardell

4

1 reference

1 December 2017

Philip E Greilich

5

1 reference

1 December 2017

1 November 2002

1 reference

1 December 2017

1 reference

1 December 2017

108

1 reference

1 December 2017

2-3

1 reference

1 December 2017

161-168

1 reference

Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Reduction of heparin binding to and inhibition of platelets by aprotinin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Influence of High-dose Aprotinin Treatment on Blood Loss and Coagulation Patterns in Patients Undergoing Myocardial Revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Measurement of platelet-mediated force development during plasma clot formation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Development of platelet contractile force as a research and clinical measure of platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans--two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Diabetes mellitus: a hypercoagulable state

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Platelet contractile force (PCF) and clot elastic modulus (CEM) are elevated in diabetic patients with chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Low-dose and high-dose aprotinin improve hemostasis in coronary operations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

The effects of aprotonin on platelets in vitro using whole blood flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

The antithrombotic and antiinflammatory mechanisms of action of aprotinin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

New antiinflammatory and platelet-preserving effects of aprotinin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Thrombin receptor-related hemostatic defect after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

Effect of fibrin structure on plasmin-mediated dissolution of plasma clots

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900403-6

7 January 2021

10.1016/S0049-3848(02)00403-6

Identifiers

DOI

1 reference

1 December 2017

1 reference